SlideShare uma empresa Scribd logo
1 de 30
Evaluate the Effects of   Ketamine  (Pain Relief Drug) in prehospital trauma care: A controlled clinical trial in Quang Tri, Vietnam Dr. PhD. Tran Kim Phung Co-operation between TMC,  Oslo University   and Quang Tri Health Service
Reason for research ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Study population ,[object Object],[object Object]
Exclusion criteria ,[object Object],[object Object],[object Object],[object Object],[object Object]
Sampling and recruitment ,[object Object],[object Object],[object Object],[object Object]
Sampling and recruitment ,[object Object],[object Object]
Main variables ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Main variables ,[object Object],[object Object]
The intervention ,[object Object],[object Object],[object Object],[object Object],[object Object]
The intervention  (continue) ,[object Object],[object Object],[object Object],[object Object]
The intervention  (continue) ,[object Object],[object Object],[object Object]
Time schedule ,[object Object],[object Object]
Main Statistic Model ,[object Object],[object Object],[object Object],[object Object]
Inclusion and Exclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Significant difference between VAS1 and VAS2, P<0.0001 No significance between the mean difference across ketamine and morphine group, P>0.05 Matched Pairs (Difference VAS1-VAS2) P= 0.1679 Test across group <.0001 <.0001 <.0001 Prob > |t| 117 140 257 N 2.75 - 3.48 3.14 - 3.75 3.06 - 3.53 95% CI 0.18 0.16 0.12 Std Error 3.11 3.44 3.29 Mean Difference 3.72 3.82 3.78 VAS2 6.84 7.26 7.07 VAS1 Morphine Ketamine
Significant difference between VAS1 and VAS2 in each  ISS group, p<0.001 <.0001 <.0001 <.0001 Prob > |t| 99 27 131 N 3.07 - 3.87 2.10 - 3.62 2.93 - 3.56 95% CI 0.20 0.37 0.16 Std Error 3.47 2,86 3.25 Mean Difference 3.78 4.15 3.70 VAS2 7.25 7.01 6.95 VAS1 Sev ere M ajor Mod erate
Significant difference between VAS1 and VAS2 in each group ,  No significance difference between the mean difference across Ketamine and morphine group in  ISS 0.33 0.47 0.53 Mean Difference Prob>F Prob>F Prob>F Test Across Groups <.0001 <.0001 <.0001 <.0001 0.0005 <.0001 Prob > |t| 47 52 55 76 15 12 N 2.67 3.11 2.59 2.93 1.39 2.22 Lower95% 3.87 4.21 3.62 3.76 3.90 4.03 Upper95% 0.30 0.27 0.26 0.21 0.59 0.41 Std Error 3.27 3.66 3.11 3.35 2.65 3.12 Mean Difference 3.65 3.89 3.69 3.70 4.09 4.22 VAS2 6.92 7.55 6.80 7.05 6.73 7.35 VAS1 Morphine Ketamine Morphine Ketamine Morphine Ketamine Severe Moderate Major ISS group
Significant difference between VAS1 and VAS2 in each group ,  No significance between the mean difference across male and female group, p>0.05 0.16 Mean Difference Prob>F Test Across Groups <.0001 <.0001 <.0001 Prob > |t| 66 191 257 N 2.62 3.08 3.06 Lower95% 3.67 3.61 3.53 Upper95% 0.26 0.13 0.12 Std Error 3.15 3.34 3.29 Mean Difference 3.70 3.81 3.78 VAS2 6.85 7.15 7.07 VAS1 FEMALE  MALE GENDER
6 15 7 14 21 n   P=0.40 P=0.45 Mean Difference   Test Across Groups   0.0068 0.0001 0.0045 0.0001 <.0001 Prob > |t|   1.54 1.65 1.13 1.98 2.11 Lower95%   5.77 3.94 3.95 4.60 3.97 Upper95%   0.82 0.53 0.58 0.61 0.45 Std Error   3.65 2.79 2.54 3.29 3.04 Mean Difference   3.82 4.28 4.4 4.02 4.15 VAS2   7.47 7.07 6.94 7.31 7.19 VAS1   Female Male Morphine Ketamine AGE < 15
[object Object],[object Object]
1.021 0.173 Mean Difference F Ratio Prob>F Test Across Groups <.0001 <.0001 <.0001 <.0001 <.0001 Prob > |t| 35 152 85 102 187 N 2.20 3.04 2.60 3.09 2.99 Lower95% 3.74 3.65 3.49 3.82 3.55 Upper95% 0.38 0.15 0.23 0.18 0.14 Std Error 2.97 3.34 3.05 3.45 3.27 Mean Difference 3.73 3.83 3.82 3.80 3.81 VAS2 6.70 7.17 6.87 7.25 7.08 VAS1 FEMALE MALE MORPHINE KETAMINE Age (15-54)
Age (15-54) ,[object Object],[object Object]
0.41 0.95 Mean Difference Prob>F Prob>F Test Across Groups <.0001 <.0001 <.0001 <.0001 <.0001 Prob > |t| 25 24 25 24 49 N 2.45 3.18 2.74 2.82 3.00 Lower95% 4.13 4.20 4.26 4.12 3.97 Upper95% 0.41 0.25 0.37 0.32 0.24 Std Error 3.29 3.69 3.5 3.47 3.48 Mean Difference 3.63 3.35 3.21 3.78 3.49 VAS2 6.91 7.04 6.71 7.25 6.98 VAS1 FEMALE MALE MORPHINE KETAMINE AGE>=55
Age >= 55 ,[object Object],[object Object]
Significantly difference between nausea and/ or vomit with much higher rate in morphine group, P<0.0001 20 27.35 32 30.77 36 MORPHINE n=117 0 0 2.14 3 5.00 7 KETAMINE n=140 Percent Nausea & vomit Percent Vomit Percent Nausea
B. Agreement   analysis VAS2 & VAS3 -0.08 - 0.08 -0.11 Agreement index (AI)=1- 2SD (Dif)  / mean level 8/117= 6.8% 7/140= 5.7% 11/257 = 4.3% Percentage (%) outliers 4.48 4.08 4.36 Agreement limit (2SDdiff ) -0.82 0.08 -0.32 Mean difference 4.13 3.78 3.92 Mean level  Morphine Ketamine Statistics Parameters
Conclusions ,[object Object],[object Object],[object Object],[object Object]
Discussions ,[object Object],[object Object]
[object Object]

Mais conteúdo relacionado

Mais procurados

NEDA in multiple sclerosis
NEDA in multiple sclerosisNEDA in multiple sclerosis
NEDA in multiple sclerosisSudhir Kumar
 
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...European School of Oncology
 
Definition of remission of ra
Definition of remission of raDefinition of remission of ra
Definition of remission of raHaifa Alshwikh
 
Aha2009 1055
Aha2009 1055Aha2009 1055
Aha2009 1055hospital
 
Stress imaging and viability assessment
Stress imaging and viability assessmentStress imaging and viability assessment
Stress imaging and viability assessmentYousra Ghzally
 
Stoppen Met Antidepressiva
Stoppen Met AntidepressivaStoppen Met Antidepressiva
Stoppen Met AntidepressivaRobHeerdink
 
Role of systemic therapy in management of laryngeal carcinoma
Role of systemic therapy in management of laryngeal carcinomaRole of systemic therapy in management of laryngeal carcinoma
Role of systemic therapy in management of laryngeal carcinomaMohammed Fathy
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...European School of Oncology
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclcfondas vakalis
 
Topical paincontrolmedication
Topical paincontrolmedicationTopical paincontrolmedication
Topical paincontrolmedicationpiushjpatel
 
Joseph Paduda
Joseph PadudaJoseph Paduda
Joseph PadudaOPUNITE
 
Topical & Transdermal Medications in Palliative Medicine
Topical & Transdermal Medications in Palliative MedicineTopical & Transdermal Medications in Palliative Medicine
Topical & Transdermal Medications in Palliative MedicineChristian Sinclair
 
CATT TRIAL DR AJAY DUDANI
CATT TRIAL DR AJAY DUDANICATT TRIAL DR AJAY DUDANI
CATT TRIAL DR AJAY DUDANIAjayDudani1
 

Mais procurados (20)

NEDA in multiple sclerosis
NEDA in multiple sclerosisNEDA in multiple sclerosis
NEDA in multiple sclerosis
 
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
NY Prostate Cancer Conference - D. Dearnaley - Session 4: Predicting clinical...
 
Definition of remission of ra
Definition of remission of raDefinition of remission of ra
Definition of remission of ra
 
Aha2009 1055
Aha2009 1055Aha2009 1055
Aha2009 1055
 
2 Drug Therapy: Revolution or Regression?
2 Drug Therapy: Revolution or Regression?2 Drug Therapy: Revolution or Regression?
2 Drug Therapy: Revolution or Regression?
 
Stress imaging and viability assessment
Stress imaging and viability assessmentStress imaging and viability assessment
Stress imaging and viability assessment
 
Research on SLGTN
 Research on SLGTN Research on SLGTN
Research on SLGTN
 
Stoppen Met Antidepressiva
Stoppen Met AntidepressivaStoppen Met Antidepressiva
Stoppen Met Antidepressiva
 
Her2 second line
Her2 second lineHer2 second line
Her2 second line
 
Role of systemic therapy in management of laryngeal carcinoma
Role of systemic therapy in management of laryngeal carcinomaRole of systemic therapy in management of laryngeal carcinoma
Role of systemic therapy in management of laryngeal carcinoma
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclc
 
Qysmia
QysmiaQysmia
Qysmia
 
Ca colon
Ca colonCa colon
Ca colon
 
Topical paincontrolmedication
Topical paincontrolmedicationTopical paincontrolmedication
Topical paincontrolmedication
 
Joseph Paduda
Joseph PadudaJoseph Paduda
Joseph Paduda
 
Ekeanyanwu_Gold
Ekeanyanwu_GoldEkeanyanwu_Gold
Ekeanyanwu_Gold
 
Topical & Transdermal Medications in Palliative Medicine
Topical & Transdermal Medications in Palliative MedicineTopical & Transdermal Medications in Palliative Medicine
Topical & Transdermal Medications in Palliative Medicine
 
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
 
CATT TRIAL DR AJAY DUDANI
CATT TRIAL DR AJAY DUDANICATT TRIAL DR AJAY DUDANI
CATT TRIAL DR AJAY DUDANI
 

Destaque

Can China's new mental health law substantially reduce the burden of illness ...
Can China's new mental health law substantially reduce the burden of illness ...Can China's new mental health law substantially reduce the burden of illness ...
Can China's new mental health law substantially reduce the burden of illness ...BinhThang
 
5. pham xuan truong
5. pham xuan truong5. pham xuan truong
5. pham xuan truongBinhThang
 
13. nguyen phuong lan
13. nguyen phuong lan13. nguyen phuong lan
13. nguyen phuong lanBinhThang
 
4. dang van chuc
4. dang van chuc4. dang van chuc
4. dang van chucBinhThang
 
2. pornnapa kku
2. pornnapa kku2. pornnapa kku
2. pornnapa kkuBinhThang
 
Version 2 presentation to host qut assessment format
Version 2 presentation to host   qut assessment formatVersion 2 presentation to host   qut assessment format
Version 2 presentation to host qut assessment formatBinhThang
 
17. chris doran ace alcohol vine presentation
17. chris doran ace alcohol vine presentation17. chris doran ace alcohol vine presentation
17. chris doran ace alcohol vine presentationBinhThang
 
Tieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van Tuan
Tieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van TuanTieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van Tuan
Tieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van TuanBinhThang
 
De cuong Nghien cuu - GS Nguyen Van Tuan
De cuong Nghien cuu - GS Nguyen Van TuanDe cuong Nghien cuu - GS Nguyen Van Tuan
De cuong Nghien cuu - GS Nguyen Van TuanBinhThang
 
9. peter hill
9. peter hill9. peter hill
9. peter hillBinhThang
 
Chien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.comChien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.comBinhThang
 
Presentation mekong conference
Presentation mekong conferencePresentation mekong conference
Presentation mekong conferenceBinhThang
 
12. michael dunne
12. michael dunne12. michael dunne
12. michael dunneBinhThang
 
11. cao my phuong risk factors of pre diabetes in adults aged 45
11. cao my phuong risk factors of pre diabetes in adults aged 4511. cao my phuong risk factors of pre diabetes in adults aged 45
11. cao my phuong risk factors of pre diabetes in adults aged 45BinhThang
 
Epidata v2.1
Epidata v2.1Epidata v2.1
Epidata v2.1BinhThang
 

Destaque (15)

Can China's new mental health law substantially reduce the burden of illness ...
Can China's new mental health law substantially reduce the burden of illness ...Can China's new mental health law substantially reduce the burden of illness ...
Can China's new mental health law substantially reduce the burden of illness ...
 
5. pham xuan truong
5. pham xuan truong5. pham xuan truong
5. pham xuan truong
 
13. nguyen phuong lan
13. nguyen phuong lan13. nguyen phuong lan
13. nguyen phuong lan
 
4. dang van chuc
4. dang van chuc4. dang van chuc
4. dang van chuc
 
2. pornnapa kku
2. pornnapa kku2. pornnapa kku
2. pornnapa kku
 
Version 2 presentation to host qut assessment format
Version 2 presentation to host   qut assessment formatVersion 2 presentation to host   qut assessment format
Version 2 presentation to host qut assessment format
 
17. chris doran ace alcohol vine presentation
17. chris doran ace alcohol vine presentation17. chris doran ace alcohol vine presentation
17. chris doran ace alcohol vine presentation
 
Tieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van Tuan
Tieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van TuanTieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van Tuan
Tieng ANh: cach dien dat trong bai bao Khoa hoc -GS Nguyen Van Tuan
 
De cuong Nghien cuu - GS Nguyen Van Tuan
De cuong Nghien cuu - GS Nguyen Van TuanDe cuong Nghien cuu - GS Nguyen Van Tuan
De cuong Nghien cuu - GS Nguyen Van Tuan
 
9. peter hill
9. peter hill9. peter hill
9. peter hill
 
Chien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.comChien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.com
 
Presentation mekong conference
Presentation mekong conferencePresentation mekong conference
Presentation mekong conference
 
12. michael dunne
12. michael dunne12. michael dunne
12. michael dunne
 
11. cao my phuong risk factors of pre diabetes in adults aged 45
11. cao my phuong risk factors of pre diabetes in adults aged 4511. cao my phuong risk factors of pre diabetes in adults aged 45
11. cao my phuong risk factors of pre diabetes in adults aged 45
 
Epidata v2.1
Epidata v2.1Epidata v2.1
Epidata v2.1
 

Semelhante a Evaluate the Effects of Ketamine for Prehospital Pain Relief in Trauma Patients: A Clinical Trial in Vietnam

MAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMAMAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMAspa718
 
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de PulmónEffyciens Marketing Online SL.
 
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...WAidid
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Sociedad Española de Cardiología
 
Exemestane Versus Tamoxifen
Exemestane Versus TamoxifenExemestane Versus Tamoxifen
Exemestane Versus Tamoxifenfondas vakalis
 
Breast MRI for early prediction of residual disease following neoadjuvant che...
Breast MRI for early prediction of residual disease following neoadjuvant che...Breast MRI for early prediction of residual disease following neoadjuvant che...
Breast MRI for early prediction of residual disease following neoadjuvant che...Wen Li
 
Switching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosisSwitching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosisDivya Shilpa
 
Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...cheweb1
 
Packer Stop Af1
Packer Stop Af1Packer Stop Af1
Packer Stop Af1enforme
 
6 frederick
6 frederick6 frederick
6 frederickspa718
 
3.Case Based Moderation Slidedeck 110_130_150.pptx
3.Case Based Moderation Slidedeck 110_130_150.pptx3.Case Based Moderation Slidedeck 110_130_150.pptx
3.Case Based Moderation Slidedeck 110_130_150.pptxBipineshSansar
 
Chronic myeloid leukemia
Chronic myeloid leukemia Chronic myeloid leukemia
Chronic myeloid leukemia Sophia Hsieh
 
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...Cytel USA
 
Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”Patwant Dhillon
 
Differentiated Thyroid Cancer Treatment.pptx
Differentiated Thyroid Cancer Treatment.pptxDifferentiated Thyroid Cancer Treatment.pptx
Differentiated Thyroid Cancer Treatment.pptxSeraj Aldeen
 
hypofractionationinbreastexperiment.pptx
hypofractionationinbreastexperiment.pptxhypofractionationinbreastexperiment.pptx
hypofractionationinbreastexperiment.pptxsvmmcradonco1
 
Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...
Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...
Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...Giuseppe Quintaliani
 

Semelhante a Evaluate the Effects of Ketamine for Prehospital Pain Relief in Trauma Patients: A Clinical Trial in Vietnam (20)

MAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMAMAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMA
 
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
 
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
 
What’s New With HER2?
What’s New With HER2?What’s New With HER2?
What’s New With HER2?
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?
 
Exemestane Versus Tamoxifen
Exemestane Versus TamoxifenExemestane Versus Tamoxifen
Exemestane Versus Tamoxifen
 
Breast MRI for early prediction of residual disease following neoadjuvant che...
Breast MRI for early prediction of residual disease following neoadjuvant che...Breast MRI for early prediction of residual disease following neoadjuvant che...
Breast MRI for early prediction of residual disease following neoadjuvant che...
 
Switching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosisSwitching therapy in Multiple sclerosis
Switching therapy in Multiple sclerosis
 
Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...
 
Packer Stop Af1
Packer Stop Af1Packer Stop Af1
Packer Stop Af1
 
6 frederick
6 frederick6 frederick
6 frederick
 
3.Case Based Moderation Slidedeck 110_130_150.pptx
3.Case Based Moderation Slidedeck 110_130_150.pptx3.Case Based Moderation Slidedeck 110_130_150.pptx
3.Case Based Moderation Slidedeck 110_130_150.pptx
 
ABC1 - P. Francis - Elderly patients
ABC1 - P. Francis - Elderly patientsABC1 - P. Francis - Elderly patients
ABC1 - P. Francis - Elderly patients
 
Chronic myeloid leukemia
Chronic myeloid leukemia Chronic myeloid leukemia
Chronic myeloid leukemia
 
CROI Review Series: HIV Drug Trials and HIV Prevention Research
CROI Review Series: HIV Drug Trials and HIV Prevention ResearchCROI Review Series: HIV Drug Trials and HIV Prevention Research
CROI Review Series: HIV Drug Trials and HIV Prevention Research
 
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
2014-10-22 EUGM | WEI | Moving Beyond the Comfort Zone in Practicing Translat...
 
Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”
 
Differentiated Thyroid Cancer Treatment.pptx
Differentiated Thyroid Cancer Treatment.pptxDifferentiated Thyroid Cancer Treatment.pptx
Differentiated Thyroid Cancer Treatment.pptx
 
hypofractionationinbreastexperiment.pptx
hypofractionationinbreastexperiment.pptxhypofractionationinbreastexperiment.pptx
hypofractionationinbreastexperiment.pptx
 
Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...
Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...
Giornate Nefrologiche Pisane 2009 - Ruggenenti la remissione della malattia r...
 

Mais de BinhThang

Những cách diễn đạt trong bài báo khoa học
Những cách diễn đạt trong bài báo khoa học Những cách diễn đạt trong bài báo khoa học
Những cách diễn đạt trong bài báo khoa học BinhThang
 
Gs nv tuan_cachviet_decuong_nckh
Gs nv tuan_cachviet_decuong_nckhGs nv tuan_cachviet_decuong_nckh
Gs nv tuan_cachviet_decuong_nckhBinhThang
 
Qut & hue university exchange power point
Qut & hue university exchange power pointQut & hue university exchange power point
Qut & hue university exchange power pointBinhThang
 
Y te cong cong la gi
Y te cong cong la giY te cong cong la gi
Y te cong cong la giBinhThang
 
Chien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.comChien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.comBinhThang
 
Programme of the 2nd international conference on public health
Programme of the 2nd international conference on public healthProgramme of the 2nd international conference on public health
Programme of the 2nd international conference on public healthBinhThang
 
19. nguyen hoang lan
19. nguyen hoang lan19. nguyen hoang lan
19. nguyen hoang lanBinhThang
 
18. truong cong dat presentation
18. truong cong dat presentation18. truong cong dat presentation
18. truong cong dat presentationBinhThang
 
17. chris doran
17. chris doran17. chris doran
17. chris doranBinhThang
 
16. hoang khanh chi
16. hoang khanh chi16. hoang khanh chi
16. hoang khanh chiBinhThang
 
14. douangphachanh xaysomphou
14. douangphachanh xaysomphou14. douangphachanh xaysomphou
14. douangphachanh xaysomphouBinhThang
 
10. doan vuong diem khanh
10. doan vuong diem khanh10. doan vuong diem khanh
10. doan vuong diem khanhBinhThang
 
8. nguyen van hai
8. nguyen van hai8. nguyen van hai
8. nguyen van haiBinhThang
 
7. nguyen dinh tung
7. nguyen dinh tung7. nguyen dinh tung
7. nguyen dinh tungBinhThang
 
6. le tan phung
6. le tan phung6. le tan phung
6. le tan phungBinhThang
 
3. linda muray l
3. linda muray l3. linda muray l
3. linda muray lBinhThang
 

Mais de BinhThang (16)

Những cách diễn đạt trong bài báo khoa học
Những cách diễn đạt trong bài báo khoa học Những cách diễn đạt trong bài báo khoa học
Những cách diễn đạt trong bài báo khoa học
 
Gs nv tuan_cachviet_decuong_nckh
Gs nv tuan_cachviet_decuong_nckhGs nv tuan_cachviet_decuong_nckh
Gs nv tuan_cachviet_decuong_nckh
 
Qut & hue university exchange power point
Qut & hue university exchange power pointQut & hue university exchange power point
Qut & hue university exchange power point
 
Y te cong cong la gi
Y te cong cong la giY te cong cong la gi
Y te cong cong la gi
 
Chien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.comChien luoc dan so 2011 2020 - ytecongcong.com
Chien luoc dan so 2011 2020 - ytecongcong.com
 
Programme of the 2nd international conference on public health
Programme of the 2nd international conference on public healthProgramme of the 2nd international conference on public health
Programme of the 2nd international conference on public health
 
19. nguyen hoang lan
19. nguyen hoang lan19. nguyen hoang lan
19. nguyen hoang lan
 
18. truong cong dat presentation
18. truong cong dat presentation18. truong cong dat presentation
18. truong cong dat presentation
 
17. chris doran
17. chris doran17. chris doran
17. chris doran
 
16. hoang khanh chi
16. hoang khanh chi16. hoang khanh chi
16. hoang khanh chi
 
14. douangphachanh xaysomphou
14. douangphachanh xaysomphou14. douangphachanh xaysomphou
14. douangphachanh xaysomphou
 
10. doan vuong diem khanh
10. doan vuong diem khanh10. doan vuong diem khanh
10. doan vuong diem khanh
 
8. nguyen van hai
8. nguyen van hai8. nguyen van hai
8. nguyen van hai
 
7. nguyen dinh tung
7. nguyen dinh tung7. nguyen dinh tung
7. nguyen dinh tung
 
6. le tan phung
6. le tan phung6. le tan phung
6. le tan phung
 
3. linda muray l
3. linda muray l3. linda muray l
3. linda muray l
 

Evaluate the Effects of Ketamine for Prehospital Pain Relief in Trauma Patients: A Clinical Trial in Vietnam

  • 1. Evaluate the Effects of Ketamine (Pain Relief Drug) in prehospital trauma care: A controlled clinical trial in Quang Tri, Vietnam Dr. PhD. Tran Kim Phung Co-operation between TMC, Oslo University and Quang Tri Health Service
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16. Significant difference between VAS1 and VAS2, P<0.0001 No significance between the mean difference across ketamine and morphine group, P>0.05 Matched Pairs (Difference VAS1-VAS2) P= 0.1679 Test across group <.0001 <.0001 <.0001 Prob > |t| 117 140 257 N 2.75 - 3.48 3.14 - 3.75 3.06 - 3.53 95% CI 0.18 0.16 0.12 Std Error 3.11 3.44 3.29 Mean Difference 3.72 3.82 3.78 VAS2 6.84 7.26 7.07 VAS1 Morphine Ketamine
  • 17. Significant difference between VAS1 and VAS2 in each ISS group, p<0.001 <.0001 <.0001 <.0001 Prob > |t| 99 27 131 N 3.07 - 3.87 2.10 - 3.62 2.93 - 3.56 95% CI 0.20 0.37 0.16 Std Error 3.47 2,86 3.25 Mean Difference 3.78 4.15 3.70 VAS2 7.25 7.01 6.95 VAS1 Sev ere M ajor Mod erate
  • 18. Significant difference between VAS1 and VAS2 in each group , No significance difference between the mean difference across Ketamine and morphine group in ISS 0.33 0.47 0.53 Mean Difference Prob>F Prob>F Prob>F Test Across Groups <.0001 <.0001 <.0001 <.0001 0.0005 <.0001 Prob > |t| 47 52 55 76 15 12 N 2.67 3.11 2.59 2.93 1.39 2.22 Lower95% 3.87 4.21 3.62 3.76 3.90 4.03 Upper95% 0.30 0.27 0.26 0.21 0.59 0.41 Std Error 3.27 3.66 3.11 3.35 2.65 3.12 Mean Difference 3.65 3.89 3.69 3.70 4.09 4.22 VAS2 6.92 7.55 6.80 7.05 6.73 7.35 VAS1 Morphine Ketamine Morphine Ketamine Morphine Ketamine Severe Moderate Major ISS group
  • 19. Significant difference between VAS1 and VAS2 in each group , No significance between the mean difference across male and female group, p>0.05 0.16 Mean Difference Prob>F Test Across Groups <.0001 <.0001 <.0001 Prob > |t| 66 191 257 N 2.62 3.08 3.06 Lower95% 3.67 3.61 3.53 Upper95% 0.26 0.13 0.12 Std Error 3.15 3.34 3.29 Mean Difference 3.70 3.81 3.78 VAS2 6.85 7.15 7.07 VAS1 FEMALE MALE GENDER
  • 20. 6 15 7 14 21 n   P=0.40 P=0.45 Mean Difference   Test Across Groups   0.0068 0.0001 0.0045 0.0001 <.0001 Prob > |t|   1.54 1.65 1.13 1.98 2.11 Lower95%   5.77 3.94 3.95 4.60 3.97 Upper95%   0.82 0.53 0.58 0.61 0.45 Std Error   3.65 2.79 2.54 3.29 3.04 Mean Difference   3.82 4.28 4.4 4.02 4.15 VAS2   7.47 7.07 6.94 7.31 7.19 VAS1   Female Male Morphine Ketamine AGE < 15
  • 21.
  • 22. 1.021 0.173 Mean Difference F Ratio Prob>F Test Across Groups <.0001 <.0001 <.0001 <.0001 <.0001 Prob > |t| 35 152 85 102 187 N 2.20 3.04 2.60 3.09 2.99 Lower95% 3.74 3.65 3.49 3.82 3.55 Upper95% 0.38 0.15 0.23 0.18 0.14 Std Error 2.97 3.34 3.05 3.45 3.27 Mean Difference 3.73 3.83 3.82 3.80 3.81 VAS2 6.70 7.17 6.87 7.25 7.08 VAS1 FEMALE MALE MORPHINE KETAMINE Age (15-54)
  • 23.
  • 24. 0.41 0.95 Mean Difference Prob>F Prob>F Test Across Groups <.0001 <.0001 <.0001 <.0001 <.0001 Prob > |t| 25 24 25 24 49 N 2.45 3.18 2.74 2.82 3.00 Lower95% 4.13 4.20 4.26 4.12 3.97 Upper95% 0.41 0.25 0.37 0.32 0.24 Std Error 3.29 3.69 3.5 3.47 3.48 Mean Difference 3.63 3.35 3.21 3.78 3.49 VAS2 6.91 7.04 6.71 7.25 6.98 VAS1 FEMALE MALE MORPHINE KETAMINE AGE>=55
  • 25.
  • 26. Significantly difference between nausea and/ or vomit with much higher rate in morphine group, P<0.0001 20 27.35 32 30.77 36 MORPHINE n=117 0 0 2.14 3 5.00 7 KETAMINE n=140 Percent Nausea & vomit Percent Vomit Percent Nausea
  • 27. B. Agreement analysis VAS2 & VAS3 -0.08 - 0.08 -0.11 Agreement index (AI)=1- 2SD (Dif) / mean level 8/117= 6.8% 7/140= 5.7% 11/257 = 4.3% Percentage (%) outliers 4.48 4.08 4.36 Agreement limit (2SDdiff ) -0.82 0.08 -0.32 Mean difference 4.13 3.78 3.92 Mean level Morphine Ketamine Statistics Parameters
  • 28.
  • 29.
  • 30.